Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 10.59B +414.4% |
| Revenue (ttm) | 622.01M +14.1% |
| Net Income | -300.91M |
| EPS | -2.17 |
| Shares Out | 140.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,272,678 |
| Open | 76.94 |
| Previous Close | 77.91 |
| Day's Range | 73.41 - 77.18 |
| 52-Week Range | 14.30 - 82.26 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | 88.17 (+17.25%) |
| Earnings Date | May 7, 2026 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price target is $88.17, which is an increase of 17.25% from the latest price.
News
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
Arrowhead (ARWR) Pharmaceuticals presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference therapeutic being developed as a potential trea...
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational...
Arrowhead presents clinical cardiometabolic data at EAS Congress
Arrowhead (ARWR) Pharmaceuticals presented new clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for ...
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-se...
Arrowhead Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Recent regulatory approvals and strong commercial launch have positioned the company for significant growth, with key phase III trial readouts expected in Q3. The pipeline focus is on cardiometabolic assets, with robust financial resources and a $3–$4 billion peak revenue opportunity projected.
Arrowhead Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company is transitioning to commercial operations while maintaining robust R&D, highlighted by a successful REDEMPLO launch and a strong pipeline in cardiometabolic, obesity, and CNS. Key data readouts are expected in Q3 2024, with premium pricing and gradual market adoption anticipated.
Arrowhead Pharmaceuticals Slides: Corporate presentation
Arrowhead Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Arrowhead price target raised to $46 from $35 at Bernstein
Bernstein raised the firm’s price target on Arrowhead (ARWR) to $46 from $35 and keeps a Market Perform rating on the shares. Biotech has had a strong start to 2026,…
Arrowhead price target raised to $90 from $80 at Chardan
Chardan raised the firm’s price target on Arrowhead (ARWR) to $90 from $80 and keeps a Buy rating on the shares post the fiscal Q2 report. The U.S. launch of…
Arrowhead reports Q2 EPS (93c), consensus ($1.11)
Reports Q2 revenue $73.7M, consensus $71.7M. “Arrowhead (ARWR) continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong ...
Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2026
REDEMPLO's U.S. launch exceeded expectations, with strong prescription growth and positive payer feedback. Major pipeline milestones are expected in Q3/Q4 2026, and the company is well-funded after significant capital raises and a lucrative licensing deal with Madrigal.
Arrowhead Pharmaceuticals Earnings release: Q2 2026
Arrowhead Pharmaceuticals released its Q2 2026 earnings on May 7, 2026, summarizing the period's financial results.
Arrowhead Pharmaceuticals Quarterly report: Q2 2026
Arrowhead Pharmaceuticals has published its Q2 2026 quarterly earnings report on May 7, 2026.
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is ho...
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
Arrowhead Pharmaceuticals (ARWR) announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (MDGL) for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference therapeutic designe...
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for AR...
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.
Arrowhead announces Australian TGA approved Redemplo for FCS
Arrowhead (ARWR) Pharmaceuticals announced that the Australian Therapeutic Goods Administration, TGA, has approved Redemplo, a small interfering RNA medicine, as an adjunct to diet to reduce triglycer...
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasira...
Arrowhead initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Arrowhead (ARWR) with an Overweight rating and $88 price target The company has a a “highly diversified” RNAi portfolio targeting a spectrum of diseases and is…
Arrowhead announces EMA recommended approval of Redemplo
Arrowhead (ARWR) Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or EMA CHMP, has adopted a positive opinion, recommending the approval o...
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHM...
This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains.
Arrowhead Pharmaceuticals stock could build on its rally in the third quarter, Morgan Stanley says.
Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Arrowhead (ARWR) to Overweight from Equal Weight with a price target of $100, up from $78. The firm sees the stock’s momentum continuing ahead of Phase 3…
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss i...